Jeff Yass’s Proshares UltraPro NASDAQ Biotechnology UBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-13,200
| Closed | -$432K | – | 11281 |
|
|
2019
Q4 | $432K | Buy |
+13,200
| New | +$351K | ﹤0.01% | 7279 |
|
|
2019
Q3 | – | Sell |
-11,100
| Closed | -$288K | – | 11179 |
|
|
2019
Q2 | $288K | Buy |
11,100
+3,100
| +39% | +$76.5K | ﹤0.01% | 8397 |
|
|
2019
Q1 | $234K | Buy |
+8,000
| New | +$227K | ﹤0.01% | 7636 |
|
|
2018
Q3 | – | Sell |
-10,900
| Closed | -$362K | – | 10694 |
|
|
2018
Q2 | $362K | Buy |
+10,900
| New | +$340K | ﹤0.01% | 7472 |
|
|
2018
Q1 | – | Sell |
-7,000
| Closed | -$235K | – | 10619 |
|
|
2017
Q4 | $235K | Buy |
+7,000
| New | +$239K | ﹤0.01% | 7984 |
|
|
2017
Q3 | – | Sell |
-21,600
| Closed | -$688K | – | 10003 |
|
|
2017
Q2 | $688K | Buy |
+21,600
| New | +$606K | ﹤0.01% | 6022 |
|
|
2016
Q4 | – | Sell |
-34,400
| Closed | -$993K | – | 10424 |
|
|
2016
Q3 | $993K | Buy |
34,400
+24,800
| +258% | +$706K | ﹤0.01% | 4814 |
|
|
2016
Q2 | $204K | Buy |
9,600
+1,100
| +13% | +$27.9K | ﹤0.01% | 7576 |
|
|
2016
Q1 | $201K | Sell |
8,500
-6,000
| -41% | -$165K | ﹤0.01% | 7969 |
|
|
2015
Q4 | $839K | Buy |
14,500
+12,460
| +611% | +$660K | ﹤0.01% | 5771 |
|
|
2015
Q3 | $91K | Buy |
+2,040
| New | +$165K | ﹤0.01% | 9184 |
|
Other funds holding UBIO
Jeff Yass's UBIO Position: Q1 2020 in Review
Jeff Yass sold out of Proshares UltraPro NASDAQ Biotechnology (UBIO) in Q1 2020, closing a stake of 33,955 shares — an estimated $1.11M sold.
Jeff Yass first reported a position in UBIO in Q4 2015 and held it in 12 quarters. The position peaked at $1.3M in Q4 2015. 1 fund tracked by Wall St. Rank holds UBIO as of Q1 2020.
- Jeff Yass reported no remaining Proshares UltraPro NASDAQ Biotechnology position as of Q1 2020 after selling out during the quarter.
- Jeff Yass sold 33,955 Proshares UltraPro NASDAQ Biotechnology shares in Q1 2020, an estimated $1.11M.
- Jeff Yass first reported a position in Proshares UltraPro NASDAQ Biotechnology in Q4 2015 and held it in 12 quarters.
- Jeff Yass's Proshares UltraPro NASDAQ Biotechnology position peaked at $1.3M in Q4 2015.
- 1 fund tracked by Wall St. Rank held Proshares UltraPro NASDAQ Biotechnology as of Q1 2020.
Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.